par Duprez, Daniel;Neuhaus, Jacqueline;Neaton, James;Kuller, Lewis L.H.;Tracy, Russell;Belloso, Waldo;De Wit, Stéphane 
;Drummond, Fraser;Lane, H Clifford;Ledergerber, Bruno;Lundgren, Jens D;Nixon, Daniel D.E.;Paton, Nicholas N.I.;Prineas, Ronald R.J.
Référence PloS one, 7, 9, A20
Publication Publié, 2012-09
;Drummond, Fraser;Lane, H Clifford;Ledergerber, Bruno;Lundgren, Jens D;Nixon, Daniel D.E.;Paton, Nicholas N.I.;Prineas, Ronald R.J.Référence PloS one, 7, 9, A20
Publication Publié, 2012-09
Article révisé par les pairs
| Résumé : | Background: The SMART study was a trial of intermittent use of antiretroviral therapy (ART) (drug conservation [DC]) versus continuous use of ART (viral suppression [VS]) as a strategy to reduce toxicities, including cardiovascular disease (CVD) risk. We studied the predictive value of high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer with CVD morbidity and mortality in HIV-infected patients who were enrolled in SMART beyond other measured CVD risk factors. |
